المؤلفون: Borghaei H; Hematology and Oncology Department, Fox Chase Cancer Center, Philadelphia, USA. Electronic address: Hossein.Borghaei@fccc.edu., de Marinis F; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy., Dumoulin D; Department of Pulmonary Medicine, Erasmus Medisch Centrum, Rotterdam, the Netherlands., Reynolds C; Ocala Cancer Center, Florida Cancer Specialists and Research Institute - North Region (SCRI), Ocala, USA., Theelen WSME; Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Percent I; North Port Cancer Center, Florida Cancer Specialists and Research Institute - South Region (SCRI), Port Charlotte, USA., Gutierrez Calderon V; Department of Medical Oncology, Hospital Regional Universitario de Málaga, Málaga, Spain., Johnson ML; Department of Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, USA., Madroszyk-Flandin A; Department of Medicine, Institut Paoli-Calmettes, Marseille, France., Garon EB; Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles., He K; Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, USA., Planchard D; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France., Reck M; Department of Thoracic Oncology, LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany., Popat S; Lung Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK., Herbst RS; Section of Medical Oncology, Yale University, New Haven., Leal TA; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta., Shazer RL; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA., Yan X; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA., Harrigan R; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA., Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

مؤلفون مشاركون: SAPPHIRE Investigators

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Jan; Vol. 35 (1), pp. 66-76. Date of Electronic Publication: 2023 Oct 20.

نوع المنشور: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/pathology , Anilides* , Pyridines*, Humans ; Docetaxel/therapeutic use ; Nivolumab/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Tumor Microenvironment

المؤلفون: Garon EB; David Geffen School of Medicine at University of California Los Angeles/TRIO-US Network, Los Angeles, USA. Electronic address: egaron@mednet.ucla.edu., Reck M; LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany., Nishio K; Department of Medical Oncology, Kindai University, Osaka, Japan., Heymach JV; Department of Thoracic/Head & Neck Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, USA; Department of Cancer Biology, University of Texas, MD Anderson Cancer Center, Houston, USA., Nishio M; Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Novello S; Department of Oncology, AOU San Luigi, University of Turin, Turin, Italy., Paz-Ares L; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain., Popat S; Royal Marsden NHS Trust, London, UK., Aix SP; Hospital Universitario 12 de Octubre, Madrid, Spain., Graham H; Eli Lilly and Company, Indianapolis, USA., Butts BD; Eli Lilly and Company, Indianapolis, USA., Visseren-Grul C; Eli Lilly and Company, Indianapolis, USA., Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.

مؤلفون مشاركون: RELAY study investigators

المصدر: ESMO open [ESMO Open] 2023 Aug; Vol. 8 (4), pp. 101580. Date of Electronic Publication: 2023 Jun 28.

نوع المنشور: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology, Humans ; Erlotinib Hydrochloride/pharmacology ; Erlotinib Hydrochloride/therapeutic use ; ErbB Receptors/genetics ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Mutation ; High-Throughput Nucleotide Sequencing ; Ramucirumab

المؤلفون: Rodríguez-Abreu D; Medical Oncology, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain. Electronic address: drodabr@gobiernodecanarias.org., Powell SF; Oncology, Sanford Health, Sioux Falls, USA., Hochmair MJ; Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria., Gadgeel S; Thoracic Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, USA., Esteban E; Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain., Felip E; Medical Oncology Department, Vall d'Hebron University, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Speranza G; Centre Integré de Cancérologie de la Montérégie, Hôpital Charles-Le Moyne, Greenfield Park, Canada., De Angelis F; Centre Integré de Cancérologie de la Montérégie, Hôpital Charles-Le Moyne, Greenfield Park, Canada., Dómine M; Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain., Cheng SY; Sunnybrook Health Sciences Centre, Toronto, Canada., Bischoff HG; Thoraxklinik, Heidelberg, Germany., Peled N; Department of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel., Reck M; LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany., Hui R; Department of Medical Oncology, Westmead Hospital and University of Sydney, Sydney, Australia., Garon EB; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA., Boyer M; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia., Kurata T; Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan., Yang J; Merck & Co., Inc., Kenilworth, USA., Pietanza MC; Merck & Co., Inc., Kenilworth, USA., Souza F; Merck & Co., Inc., Kenilworth, USA., Garassino MC; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; University of Chicago Medicine & Biological Sciences, Knapp Center for Biomedical Discovery, Chicago, USA.

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jul; Vol. 32 (7), pp. 881-895. Date of Electronic Publication: 2021 Apr 22.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/drug therapy, Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Pemetrexed/therapeutic use ; Platinum/therapeutic use ; Randomized Controlled Trials as Topic

المؤلفون: Ponce Aix S; Hospital doce de Octubre, Medical Oncology Department Thoracic Cancer and Early Drug Development Unit, Madrid, Spain. Electronic address: sponceaix@gmail.com., Novello S; Department of Oncology, University of Turin, AOU San Luigi, Orbassano, Italy., Garon EB; David Geffen School of Medicine at University of California Los Angeles/TRIO-US Network, Santa Monica, CA, United States., Nakagawa K; Kindai University Faculty of Medicine, Osaka, Japan., Nadal E; Catalan Institute of Oncology L'Hospitalet, Barcelona, Spain., Moro-Sibilot D; Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, France., Alonso Garcia M; Hospital Virgen del Rocío, Sevilla, Spain., Fabre E; GHU Paris Ouest, Hôpital Européen Georges-Pompidou Service Oncologie Thoracique, Paris, France., Frimodt-Moller B; Eli Lilly and Company, Copenhagen, Denmark., Zimmermann AH; Eli Lilly and Company, Indianapolis, Indiana, United States., Visseren-Grul CM; Eli Lilly and Company, Utrecht, Netherlands., Reck M; Lungen Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.

مؤلفون مشاركون: RELAY investigators

المصدر: Cancer treatment and research communications [Cancer Treat Res Commun] 2021; Vol. 27, pp. 100378. Date of Electronic Publication: 2021 Apr 19.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101694651 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-2942 (Electronic) Linking ISSN: 24682942 NLM ISO Abbreviation: Cancer Treat Res Commun Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Brain Neoplasms/*secondary , Carcinoma, Non-Small-Cell Lung/*drug therapy , Lung Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/secondary ; Double-Blind Method ; Drug Eruptions/etiology ; ErbB Receptors/genetics ; Erlotinib Hydrochloride/administration & dosage ; Europe ; Female ; Humans ; Hypertension/chemically induced ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Mutation ; Placebos/administration & dosage ; Progression-Free Survival ; Response Evaluation Criteria in Solid Tumors ; Survival Rate ; United States ; Young Adult ; Ramucirumab

المؤلفون: Hastings K; Yale Cancer Center, New Haven., Yu HA; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York., Wei W; Yale School of Public Health, New Haven., Sanchez-Vega F; Human Oncology and Pathogenesis Program; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering, New York., DeVeaux M; Yale School of Public Health, New Haven., Choi J; Department of Genetics, Yale School of Medicine, New Haven., Rizvi H; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York., Lisberg A; David Geffen School of Medicine, University of California Los Angeles, Los Angeles., Truini A; Yale Cancer Center, New Haven., Lydon CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston., Liu Z; Department of Pathology, Yale School of Medicine, New Haven., Henick BS; Herbert Irving Comprehensive Cancer Center, Columbia University, New York; Department of Medicine, Columbia University Medical Center, New York., Wurtz A; Yale Cancer Center, New Haven., Cai G; Department of Pathology, Yale School of Medicine, New Haven., Plodkowski AJ; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York., Long NM; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York., Halpenny DF; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York., Killam J; Department of Diagnostic Radiology, Yale School of Medicine, New Haven., Oliva I; Department of Diagnostic Radiology, Yale School of Medicine, New Haven., Schultz N; Human Oncology and Pathogenesis Program; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering, New York; Department of Epidemiology and Biostatistics., Riely GJ; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York., Arcila ME; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York., Ladanyi M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York., Zelterman D; Yale School of Public Health, New Haven., Herbst RS; Yale Cancer Center, New Haven; Department of Medicine (Section of Medical Oncology), Yale School of Medicine, New Haven, USA., Goldberg SB; Yale Cancer Center, New Haven; Department of Medicine (Section of Medical Oncology), Yale School of Medicine, New Haven, USA., Awad MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston., Garon EB; David Geffen School of Medicine, University of California Los Angeles, Los Angeles., Gettinger S; Yale Cancer Center, New Haven; Department of Medicine (Section of Medical Oncology), Yale School of Medicine, New Haven, USA., Hellmann MD; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York. Electronic address: hellmanm@mskcc.org., Politi K; Yale Cancer Center, New Haven; Department of Pathology, Yale School of Medicine, New Haven; Department of Medicine (Section of Medical Oncology), Yale School of Medicine, New Haven, USA. Electronic address: katerina.politi@yale.edu.

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 Aug 01; Vol. 30 (8), pp. 1311-1320.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Immunological/*pharmacology , Biomarkers, Tumor/*genetics , Carcinoma, Non-Small-Cell Lung/*drug therapy , Lung Neoplasms/*drug therapy, Aged ; Alleles ; Antineoplastic Agents, Immunological/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; B7-H1 Antigen/metabolism ; Biomarkers, Tumor/antagonists & inhibitors ; Biomarkers, Tumor/metabolism ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/mortality ; Drug Resistance, Neoplasm/genetics ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Female ; Genetic Heterogeneity ; Humans ; Lung/immunology ; Lung/pathology ; Lung Neoplasms/genetics ; Lung Neoplasms/immunology ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Mutation ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Programmed Cell Death 1 Receptor/metabolism ; Progression-Free Survival ; Retrospective Studies ; Tobacco Smoking/adverse effects ; Tobacco Smoking/epidemiology

المؤلفون: Herbst RS; Department of Medical Oncology, Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, USA. Electronic address: roy.herbst@yale.edu., Baas P; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Perez-Gracia JL; Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain., Felip E; Lung Cancer Unit, Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea., Han JY; Division of Translational & Clinical Research, National Cancer Center, Goyang, Republic of Korea., Molina JR; Department of Oncology, Mayo Clinic, Rochester, USA., Kim JH; Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Gyeonggi-Do, Republic of Korea., Dubos Arvis C; Department of Medicine, Centre François Baclesse, Caen, France., Ahn MJ; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Majem M; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Fidler MJ; Division of Hematology Oncology, Rush University Medical Center, Chicago, USA., Surmont V; Department of Respiratory Medicine/Thoracic Oncology, Universitar Ziekenhuis Ghent, Ghent, Belgium., de Castro G Jr; Department of Medical Oncology, Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil., Garrido M; Department of Hemato-Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile., Shentu Y; Department of Clinical Research, Merck & Co. Inc., Kenilworth, USA., Emancipator K; Department of Clinical Research, Merck & Co. Inc., Kenilworth, USA., Samkari A; Department of Clinical Research, Merck & Co. Inc., Kenilworth, USA., Jensen EH; Department of Clinical Research, Merck & Co. Inc., Kenilworth, USA., Lubiniecki GM; Department of Clinical Research, Merck & Co. Inc., Kenilworth, USA., Garon EB; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, USA.

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 Feb 01; Vol. 30 (2), pp. 281-289.

نوع المنشور: Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , B7-H1 Antigen/*metabolism , Carcinoma, Non-Small-Cell Lung/*mortality , Carcinoma, Squamous Cell/*mortality , Lung Neoplasms/*mortality , Specimen Handling/*methods, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Biopsy ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/metabolism ; Carcinoma, Squamous Cell/pathology ; Docetaxel/administration & dosage ; Female ; Follow-Up Studies ; Humans ; International Agencies ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Paraffin Embedding ; Prognosis ; Survival Rate ; Young Adult

المؤلفون: Hui R; Medical Oncology, Westmead Hospital and the University of Sydney, Sydney, Australia., Garon EB; Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, USA., Goldman JW; Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, USA., Leighl NB; Department of Medicine, Princess Margaret Cancer Centre, Toronto, Canada., Hellmann MD; Hematology/Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA., Patnaik A; Oncology and Hematology Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio, TX, USA., Gandhi L; Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Eder JP; Medical Oncology, Yale University, New Haven, CT, USA., Ahn MJ; Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Horn L; Thoracic Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN, USA., Felip E; Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Carcereny E; Medical Oncology, Catalan Institute of Oncology Badalona, Badalona, Spain., Rangwala R; Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA., Lubiniecki GM; Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA., Zhang J; Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA., Emancipator K; Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA., Roach C; Companion Diagnostics, Dako, an Agilent Technologies Company, Carpinteria, CA, USA., Rizvi NA; Thoracic Oncology, Columbia University, New York, USA.

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2017 Apr 01; Vol. 28 (4), pp. 874-881.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*administration & dosage , Antineoplastic Agents/*administration & dosage , B7-H1 Antigen/*antagonists & inhibitors , Carcinoma, Non-Small-Cell Lung/*drug therapy , Lung Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Agents/adverse effects ; Carcinoma, Non-Small-Cell Lung/mortality ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Female ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Treatment Outcome

المؤلفون: Giaccone G; National Cancer Institute, Bethesda, MD, USA. Electronic address: gg496@georgetown.edu., Bazhenova LA; Moores Cancer Center, UC San Diego, La Jolla, CA, USA., Nemunaitis J; Mary Crowley Cancer Research Centers, Dallas, TX, USA., Tan M; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA., Juhász E; Korányi National Institute for TB and Pulmonology, Budapest, Hungary., Ramlau R; Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznań University of Medical Sciences, Poznan, Poland., van den Heuvel MM; Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Thoracic Oncology, Amsterdam, Netherlands., Lal R; Guy's Hospital, King's Health Partners, London, England, United Kingdom., Kloecker GH; James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA., Eaton KD; Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA., Chu Q; Cross Cancer Institute, Edmonton, Alberta, Canada., Dunlop DJ; Royal Infirmary, Glasgow, Scotland, United Kingdom., Jain M; Noble Hospital, Pune, India., Garon EB; University of California, Los Angeles, Los Angeles, CA, USA., Davis CS; CSD Biostatistics, Tucson, AZ, USA., Carrier E; NovaRx Corporation, San Diego, CA, USA., Moses SC; NovaRx Corporation, San Diego, CA, USA., Shawler DL; NovaRx Corporation, San Diego, CA, USA., Fakhrai H; NovaRx Corporation, San Diego, CA, USA.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2015 Nov; Vol. 51 (16), pp. 2321-9. Date of Electronic Publication: 2015 Aug 14.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cancer Vaccines/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , Lung Neoplasms/*drug therapy , Maintenance Chemotherapy/*methods, Adult ; Aged ; Cancer Vaccines/adverse effects ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease Progression ; Disease-Free Survival ; Double-Blind Method ; Female ; Humans ; Intention to Treat Analysis ; Kaplan-Meier Estimate ; Lung Neoplasms/immunology ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Proportional Hazards Models ; Time Factors ; Treatment Outcome